Recce Ltd has released a press release.
Corporate Presentation - Biotech Investor Lunch
Filed with ASX ·
6ix hasn’t read this filing yet.
Recce Pharmaceuticals Ltd. on 6ix
In the deck
Earlier from Recce Pharmaceuticals
- Phase I Clinical Trial R327 Advances to High Dose Cohort
- Anti-Viral Patent Granted in Hong Kong
- Positive safety data from 4th Cohort -Phase I Clinical Trial
- $3.08m R&D Rebate Received
- Safety Committee Clears PhI R327 Dose Increase
Later from Recce Pharmaceuticals
- Phase I Clinical Trial R327 Advances to 4000mg
- Phase I Positive Safety Data - 4000mg Complete
- Corporate Presentation - Aussie Equities Day 2022
- Phase I Clinical Trial of R327 I.V. - 6000mg Complete
- Appendix 4E
Follow Recce Pharmaceuticals into a list and get an email when it puts out news.
Follow Recce Pharmaceuticals